Cargando…

Health Economic Aspects of Chimeric Antigen Receptor T-cell Therapies for Hematological Cancers: Present and Future

Since 2018, 2 chimeric antigen receptor (CAR) T-cell therapies received approval from the European Medicine Agency, with list prices around 320 000 Euro (€) (EUR) per treatment. These high prices raise concerns for patient access and the sustainability of healthcare systems. We aimed to estimate the...

Descripción completa

Detalles Bibliográficos
Autores principales:	Heine, Renaud, Thielen, Frederick W., Koopmanschap, Marc, Kersten, Marie José, Einsele, Hermann, Jaeger, Ulrich, Sonneveld, Pieter, Sierra, Jorge, Smand, Carin, Uyl-de Groot, Carin A.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Lippincott Williams & Wilkins 2021
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8051992/ https://www.ncbi.nlm.nih.gov/pubmed/33880433 http://dx.doi.org/10.1097/HS9.0000000000000524

Ejemplares similares

Unequal Access to Newly Registered Cancer Drugs Leads to Potential Loss of Life-Years in Europe
por: Uyl-de Groot, Carin A., et al.
Publicado: (2020)

Cost‐effectiveness of Anti‐CD19 chimeric antigen receptor T‐Cell therapy in pediatric relapsed/refractory B‐cell acute lymphoblastic leukemia. A societal view
por: Thielen, Frederick W., et al.
Publicado: (2020)

Multinomial network meta-analysis using response rates: relapsed/refractory multiple myeloma treatment rankings differ depending on the choice of outcome
por: van Beurden-Tan, Chrissy H. Y., et al.
Publicado: (2022)

Economic evaluations of big data analytics for clinical decision-making: a scoping review
por: Bakker, Lytske, et al.
Publicado: (2020)

Making Change Happen in Health
por: Horgan, Denis, et al.
Publicado: (2017)

Lenalidomide as maintenance treatment for patients with multiple myeloma after autologous stem cell transplantation: A pharmaco‐economic assessment
por: Uyl‐de Groot, Carin A., et al.
Publicado: (2020)

Efficacy of first-line treatments for multiple myeloma patients not eligible for stem cell transplantation: a network meta-analysis
por: Blommestein, Hedwig M., et al.
Publicado: (2019)

Analysis of patient reported outcomes included in the registrational clinical trials of nivolumab for advanced non-small cell lung cancer
por: Zaim, Remziye, et al.
Publicado: (2022)

Adjuvant Trastuzumab Therapy for Early HER2-Positive Breast Cancer in Iran: A Cost-Effectiveness and Scenario Analysis for an Optimal Treatment Strategy
por: Ansaripour, Amir, et al.
Publicado: (2017)

How can we discover the most valuable types of big data and artificial intelligence-based solutions? A methodology for the efficient development of the underlying analytics that improve care
por: Bakker, Lytske, et al.
Publicado: (2021)

Cost-effectiveness of first line nivolumab-ipilimumab combination therapy for advanced non-small cell lung cancer: A systematic review and methodological quality assessment
por: Zaim, Remziye, et al.
Publicado: (2023)

Incorporating risk preferences of patients in the valuation of immune checkpoint inhibitors for non-small cell lung cancer
por: Zaim, Remziye, et al.
Publicado: (2023)

A Practical Guide for Using Registry Data to Inform Decisions About the Cost Effectiveness of New Cancer Drugs: Lessons Learned from the PHAROS Registry
por: Blommestein, Hedwig M., et al.
Publicado: (2015)

Addressing the challenge of high-priced prescription drugs in the era of precision medicine: A systematic review of drug life cycles, therapeutic drug markets and regulatory frameworks
por: van der Gronde, Toon, et al.
Publicado: (2017)

Expanded Access as a source of real‐world data: An overview of FDA and EMA approvals
por: Polak, Tobias B., et al.
Publicado: (2020)

Cost-effectiveness and budget impact of pembrolizumab+axitinib versus sunitinib in patients with advanced clear-cell renal cell carcinoma in the Netherlands
por: Xander, Nicolas S. H., et al.
Publicado: (2023)

Long-term Outcomes in Patients With Multiple Myeloma: A Retrospective Analysis of the Dutch Population-based HAematological Registry for Observational Studies (PHAROS)
por: Verelst, Silvia G.R., et al.
Publicado: (2018)

Onderdiagnostiek bij kanker door de COVID-19-crisis naar diagnose, leeftijd en provincie: Een cruciale rol voor eerstelijnszorgverleners
por: Uyl-de Groot, Carin A., et al.
Publicado: (2020)

Regulatory Approval, Reimbursement, and Clinical Use of Cyclin-Dependent Kinase 4/6 Inhibitors in Metastatic Breast Cancer in the Netherlands
por: Luyendijk, Marianne, et al.
Publicado: (2023)

Health-related quality of life of multiple sclerosis patients: a European multi-country study
por: Visser, Laurenske A., et al.
Publicado: (2021)

Cost-effectiveness of Novel Treatment Sequences for Transplant-Ineligible Patients With Multiple Myeloma
por: Blommestein, Hedwig M., et al.
Publicado: (2021)

Real-world data from expanded access programmes in health technology assessments: a review of NICE technology appraisals
por: Polak, Tobias B, et al.
Publicado: (2022)

Fair Pricing of Innovative Medicines: An EHA Position Paper
por: Hagenbeek, Anton, et al.
Publicado: (2020)

Hospital-based or home-based administration of oncology drugs? A micro-costing study comparing healthcare and societal costs of hospital-based and home-based subcutaneous administration of trastuzumab
por: Franken, Margreet, et al.
Publicado: (2020)

Costs of Newly Funded Proton Therapy Using Time-Driven Activity-Based Costing in The Netherlands
por: Chen, Yi Hsuan, et al.
Publicado: (2023)

Real-world cost-effectiveness of cetuximab in the third-line treatment of metastatic colorectal cancer based on patient chart review in the Netherlands
por: Uyl-de Groot, Carin A., et al.
Publicado: (2018)

First-line tyrosine kinase inhibitors in EGFR mutation-positive non-small-cell lung cancer: a network meta-analysis
por: Holleman, Marscha S, et al.
Publicado: (2019)

Use of data-mining to support real-world cost analyses: An example using HER2-positive breast cancer in Iran
por: Ansaripour, Amir, et al.
Publicado: (2018)

Cost-effectiveness analysis of the first-line EGFR-TKIs in patients with non-small cell lung cancer harbouring EGFR mutations
por: Holleman, Marscha S., et al.
Publicado: (2019)

Medical Resource Use and Medical Costs for Radiotherapy-Related Adverse Effects: A Systematic Review
por: Chen, Yi Hsuan, et al.
Publicado: (2022)

Variation in revascularisation use and outcomes of patients in hospital with acute myocardial infarction across six high income countries: cross sectional cohort study
por: Cram, Peter, et al.
Publicado: (2022)

Cost-Effectiveness of Hypothetical New Cancer Drugs in Patients with Advanced Small-Cell Lung Cancer: Results of a Markov Chain Model
por: Uyl-de Groot, Carin A, et al.
Publicado: (2006)

Cost-effectiveness of a Pharmacogenomic Test for Stratified Isoniazid Dosing in Treatment of Active Tuberculosis
por: Rens, Neil E, et al.
Publicado: (2020)

Cost-Effectiveness Analysis of MammaPrint(®) to Guide the Use of Endocrine Therapy in Patients with Early-Stage Breast Cancer
por: Luyendijk, Marianne, et al.
Publicado: (2023)

Barriers to patient enrolment in phase III cancer clinical trials: interviews with clinicians and pharmaceutical industry representatives
por: Dane, Aniek, et al.
Publicado: (2022)

Generating Evidence from Expanded Access Use of Rare Disease Medicines: Challenges and Recommendations
por: Polak, Tobias B., et al.
Publicado: (2022)

Assessing the impact of caregiving on informal caregivers of adults with a mental disorder in OECD countries: A systematic literature review of concepts and their respective questionnaires
por: Bremmers, Leonarda G. M., et al.
Publicado: (2022)

How Do Shifts in Patients with Mental Health Problems’ Formal and Informal Care Utilization Affect Informal Caregivers?: A COVID-19 Case Study
por: Bremmers, Leonarda G. M., et al.
Publicado: (2022)

Extrapolating empirical long-term survival data: the impact of updated follow-up data and parametric extrapolation methods on survival estimates in multiple myeloma
por: Bakker, LJ, et al.
Publicado: (2023)

Chimeric Antigen Receptor T Cell Therapy in Hematology
por: Ataca, Pınar, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_e7lvdqn5rgfr4tv0916vk4dhon